These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 22695339)
21. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology. Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176 [TBL] [Abstract][Full Text] [Related]
22. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218 [TBL] [Abstract][Full Text] [Related]
23. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151 [TBL] [Abstract][Full Text] [Related]
24. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer. Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084 [TBL] [Abstract][Full Text] [Related]
25. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901 [TBL] [Abstract][Full Text] [Related]
26. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. Radhakrishnan V; Kumar R; Malhotra A; Bakhshi S J Nucl Med; 2012 Feb; 53(2):191-8. PubMed ID: 22251556 [TBL] [Abstract][Full Text] [Related]
27. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076 [TBL] [Abstract][Full Text] [Related]
28. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Kumar A; Kumar R; Seenu V; Gupta SD; Chawla M; Malhotra A; Mehta SN Eur Radiol; 2009 Jun; 19(6):1347-57. PubMed ID: 19214522 [TBL] [Abstract][Full Text] [Related]
29. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy. Lee SM; Bae SK; Kim TH; Yoon HK; Jung SJ; Park JS; Kim CK Clin Nucl Med; 2014 Oct; 39(10):882-6. PubMed ID: 25072926 [TBL] [Abstract][Full Text] [Related]
30. A Randomized Feasibility Study of Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475 [TBL] [Abstract][Full Text] [Related]
31. Utility of FDG-PET/CT in the evaluation of the response of locally advanced breast cancer to neoadjuvant chemotherapy. Ogino K; Nakajima M; Kakuta M; Hayashi M; Yamaguchi S; Tsuchioka T; Kubota K; Sakamoto S; Kato H Int Surg; 2014; 99(4):309-18. PubMed ID: 25058758 [TBL] [Abstract][Full Text] [Related]
32. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer. García Vicente AM; Cruz Mora MÁ; León Martín AA; Muñoz Sánchez Mdel M; Relea Calatayud F; Van Gómez López O; Espinosa Aunión R; Gonzalez Ageitos A; Soriano Castrejón A Tumour Biol; 2014 Nov; 35(11):11613-20. PubMed ID: 25139100 [TBL] [Abstract][Full Text] [Related]
33. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer. García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013 [TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954 [TBL] [Abstract][Full Text] [Related]
35. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax. Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189 [TBL] [Abstract][Full Text] [Related]
36. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746 [TBL] [Abstract][Full Text] [Related]
37. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks? Perez RO; Habr-Gama A; São Julião GP; Gama-Rodrigues J; Sousa AH; Campos FG; Imperiale AR; Lynn PB; Proscurshim I; Nahas SC; Ono CR; Buchpiguel CA Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1159-65. PubMed ID: 22580120 [TBL] [Abstract][Full Text] [Related]
38. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0. Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803 [TBL] [Abstract][Full Text] [Related]
39. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581 [TBL] [Abstract][Full Text] [Related]
40. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy? Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]